Who are Apitox - pure honeybee toxin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): bee venom.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apitox-pure-honeybee-toxin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Apitox - pure honeybee toxin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apitox - pure honeybee toxin (Apitox - pure honeybee toxin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Natural product immunomodulator. Area: Immunology / Rheumatology.

phase 3 Natural product immunomodulator Phospholipase A2, melittin, multiple immune cell receptors Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Apitox - pure honeybee toxin (Apitox - pure honeybee toxin) — Apimeds, Inc.. Apitoxin, the active component of honeybee venom, exerts anti-inflammatory and immunomodulatory effects through phospholipase A2 and other peptide components that modulate immune cell activity and reduce inflammatory mediators.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apitox - pure honeybee toxin TARGET	Apitox - pure honeybee toxin	Apimeds, Inc.	phase 3	Natural product immunomodulator	Phospholipase A2, melittin, multiple immune cell receptors
bee venom	bee venom	Assistance Publique - Hôpitaux de Paris	marketed	Natural product immunomodulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Natural product immunomodulator class)

Apimeds, Inc. · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apitox - pure honeybee toxin — Competitive Intelligence Brief. https://druglandscape.com/ci/apitox-pure-honeybee-toxin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab